TAIKO PHARMACEUTICAL CO.,LTD.

Transcripts Taiko Pharmaceutical Co.,Ltd.

Equities

4574

JP3442200006

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-22 EDT			5-day change	1st Jan Change
382 ^JPY	-2.55%		-8.61%	+26.07%

02-09	Taiko Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Year Ending December 2024	CI
2023	Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2023.	CI

Transcripts

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Taiko Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022	22-11-11	CI
Taiko Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Year ending December 31, 2022	22-08-12	CI
Taiko Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Quarter End December 2021	21-11-09	CI
Taiko Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Quarter End December 2021	21-08-06	CI
Taiko Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Quarter End December 2021	21-05-07	CI
Taiko Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Year 2021	21-02-12	CI
Taiko Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Period Ending December 2020	20-11-12	CI
Taiko Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Year Ended December 2020	20-08-12	CI
Taiko Pharmaceutical Co.,Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended March 31, 2020; Provides Earnings Guidance for the Period Ending December 2020	20-05-12	CI
Taiko Pharmaceutical Co.,Ltd. Announces Consolidated and Non-Consolidated Earnings Results for Period Ended March 31, 2019; Provides Consolidated Earnings Guidance for Period Ending March 31, 2020	19-05-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW